Clinical trial
Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
NCT00255281 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00255281 |
|---|---|
| Title | Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation |
| Official title | A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | AZD7009, no generic name available |
| Enrollment | 160 |
| Start date | Sep 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Nov 18, 2005 |
| Last update posted | Dec 6, 2007 |
| Countries | Denmark, Finland, Germany, Hungary, Netherlands, Norway, Poland, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: